Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief 2020:1–8.

Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019;381:2440–50. https://doi.org/10.1056/NEJMsa1909301.

World health statistics. – Monitoring health for the SDGs. Sustainable Development Goals. Geneva: World Health Organization; 2023;2023.

Google Scholar 

Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE. 2021;16:e0247307. https://doi.org/10.1371/journal.pone.0247307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36:44–58. https://doi.org/10.1007/s12325-018-0824-8.

Article  PubMed  Google Scholar 

Doane MJ, Bessonova L, Friedler HS, Mortimer KM, Cheng H, Brecht T, et al. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022;22:114. https://doi.org/10.1186/s12888-022-03758-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiat. 2020;7:64–77. https://doi.org/10.1016/S2215-0366(19)30416-X.

Article  PubMed  PubMed Central  Google Scholar 

Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong M-L. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry. 2016;6:e759–e759. https://doi.org/10.1038/tp.2016.25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018:k1951. https://doi.org/10.1136/bmj.k1951.

•• Bruno CD, Harmatz JS, Duan SX, Zhang Q, Chow CR, Greenblatt DJ. Effect of lipophilicity on drug distribution and elimination: influence of obesity. Br J Clin Pharmacol. 2021;87:3197–205. https://doi.org/10.1111/bcp.14735. Lipophilicity correlates with increased volume of distribution of a drug in people with obesity and may be used as a factor when considering whether pharmacokinetics may be altered in people with obesity.

Article  CAS  PubMed  Google Scholar 

Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33. https://doi.org/10.1111/j.1365-2125.2004.02157.x.

Article  PubMed  PubMed Central  Google Scholar 

Greenblatt DJ, Bruno CD, Harmatz JS, Dawson-Hughes B, Zhang Q, Li C, et al. Estimation of absolute and relative body fat content using noninvasive surrogates: can DXA be bypassed? J Clin Pharmacol. 2023;63(Supp2):s35–s47.

PubMed  Google Scholar 

Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87. https://doi.org/10.2165/11318100-000000000-00000.

Article  CAS  PubMed  Google Scholar 

Jain R, Chung S, Jain L, Khurana M, Lau S, Lee J, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77–89. https://doi.org/10.1038/clpt.2011.104.

Article  CAS  PubMed  Google Scholar 

Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304. https://doi.org/10.2165/11599410-000000000-00000.

Article  CAS  PubMed  Google Scholar 

Smit C, De Hoogd S, Brüggemann RJ, Knibbe CA. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14:275–85. https://doi.org/10.1080/17425255.2018.1440287.

Article  CAS  PubMed  Google Scholar 

•• Greenblatt DJ, Bruno CD, Harmatz JS, Zhang Q, Chow CR. Drug disposition in subjects with obesity: the research work of Darrell R. Abernethy J Clin Pharmacol. 2022;62:1350–63. https://doi.org/10.1002/jcph.2093. Provides a brief history of the research on the effects of obesity on pharmacokinetics dating back to the 1970s. Despite the knowledge that obesity can affect pharmacokinetics, there are no current requirements to study people with obesity during the drug approval process.

Article  CAS  PubMed  Google Scholar 

Zhang T, Krekels EHJ, Smit C, Knibbe CAJ. Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes. Expert Opin Drug Metab Toxicol. 2022;18:657–74. https://doi.org/10.1080/17425255.2022.2132931.

Article  CAS  PubMed  Google Scholar 

Chouinard V-A, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, et al. Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res. 2016;237:304–10. https://doi.org/10.1016/j.psychres.2016.01.024.

Article  PubMed  Google Scholar 

Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8:390. https://doi.org/10.4239/wjd.v8.i8.390.

Article  PubMed  PubMed Central  Google Scholar 

• Bruno CD, Elmokadem A, Housand C, Jordie EB, Chow CR, Laughren TP, et al. Impact of obesity on brexpiprazole pharmacokinetics: proposal for improved initiation of treatment. J Clin Pharmacol. 2022;62:55–65. https://doi.org/10.1002/jcph.1947. Brexpiprazole half-life is prolonged in people with obesity, leading to delayed attainment of effective concentrations.

Article  CAS  PubMed  Google Scholar 

Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine disposition in obesity: potential implications for patient safety. J Clin Psychopharmacol. 2018;38:172–9. https://doi.org/10.1097/JCP.0000000000000861.

Article  CAS  PubMed  Google Scholar 

Bruno CD, Greenblatt DJ, Harmatz JS, Chow CR. Clinical consequences of altered drug disposition in obesity: call for change. J Clin Pharmacol. 2023;63(Supp2):s25–s34.

PubMed  Google Scholar 

Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23:369–76. https://doi.org/10.1002/j.1552-4604.1983.tb02750.x.

Article  CAS  PubMed  Google Scholar 

• Wasmann RE, Smit C, Van Donselaar MH, Van Dongen EPA, Wiezer RMJ, Verweij PE, et al. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020;75:1006–13. https://doi.org/10.1093/jac/dkz546. Posaconazole plasma concentrations are lower in people with obesity after IV dosing. This could lead to treatment failure due to underdosing.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR. Sustained impairment of lurasidone clearance after discontinuation of posaconazole: impact of obesity, and implications for patient safety. J Clin Psychopharmacol. 2018;38:289–95. https://doi.org/10.1097/JCP.0000000000000892.

Article  CAS  PubMed  Google Scholar 

Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ. Persistence of a posaconazole-mediated drug-drug interaction with ranolazine after cessation of posaconazole administration: impact of obesity and implications for patient safety. J Clin Pharmacol. 2018;58:1436–42. https://doi.org/10.1002/jcph.1257.

Article  CAS  PubMed  Google Scholar 

Wasmann RE, Smit C, Ter Heine R, Koele SE, Van Dongen EPH, Wiezer RMJ, et al. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. J Antimicrob Chemother. 2019;74:978–85. https://doi.org/10.1093/jac/dky554.

Article  CAS  PubMed  Google Scholar 

Maseda E, Grau S, Luque S, Castillo-Mafla M-P, Suárez-de-la-Rica A, Montero-Feijoo A, et al. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care. 2018;22:94. https://doi.org/10.1186/s13054-018-2019-8.

Article  PubMed  PubMed Central  Google Scholar 

Brill MJE, Houwink API, Schmidt S, Van Dongen EPA, Hazebroek EJ, Van Ramshorst B, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014;69:715–23. https://doi.org/10.1093/jac/dkt444.

Article  CAS  PubMed  Google Scholar 

• Pinner NA, Tapley NG, Barber KE, Stover KR, Wagner JL. Effect of obesity on clinical failure of patients treated with β-lactams. Open Forum Infect Dis 2021;8:ofab212. https://doi.org/10.1093/ofid/ofab212. Patients with obesity who need treatment with beta-lactam antibiotics have higher rates of treatment failure compared to patients without obesity. Providing obesity-specific dosing recommendations for these drugs may improve patient outcomes.

Simpson T, Shah S, Pogue JM, Wu J. Safety and efficacy of high-dose cefazolin therapy in obesity. vol. 6(Suppl 2). Open Forum Infect Dis. 2019;S570. https://doi.org/10.1093/ofid/ofz360.1426.

Andrews LM, De Winter BCM, Tang J-T, Shuker N, Bouamar R, Van Schaik RHN, et al. Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose. Transplant Direct. 2017;3:e129. https://doi.org/10.1097/TXD.0000000000000644.

Article  PubMed  PubMed Central  Google Scholar 

• Breslin NT, Hedvat J, Salerno DM, Jandovitz N, Patel C, Lee S, et al. Comparing weight‐based dosing of tacrolimus XR in obese and non‐obese renal transplant recipients. Clin Transplant 2022;36. https://doi.org/10.1111/ctr.14529. Tacrolimus dosing based on total body weight results in supratherapeutic exposure in patients with obesity. Dosing should instead be based on ideal body weight.

Chinnadurai R, Ibrahim ST, Tay T, Bhutani S, Kalra PA. Body weight-based initial dosing of tacrolimus in renal transplantation: is this an ideal approach? J Ren Care. 2021;47:51–7. https://doi.org/10.1111/jorc.12339.

Article  PubMed  Google Scholar 

Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84:363–7. https://doi.org/10.1016/j.contraception.2011.02.009.

Article  CAS  PubMed  Google Scholar 

Edelman AB, Cherala G, Blue SW, Erikson DW, Jensen JT. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception. 2016;94:52–7. https://doi.org/10.1016/j.contraception.2016.03.006.

Article  CAS  PubMed